An Unusual Case of Ototoxicity with Use of Oral Vancomycin

Introduction. Systemic absorption of oral vancomycin is poor due to the size of the molecule and its pharmacokinetics. It has an elimination half life of 5–11 hours in patients with normal renal function. We present a rare case of ototoxicity after oral vancomycin administration and detectable serum...

Full description

Saved in:
Bibliographic Details
Main Authors: Umut Gomceli, Srija Vangala, Cosmina Zeana, Paul J. Kelly, Manisha Singh
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Case Reports in Infectious Diseases
Online Access:http://dx.doi.org/10.1155/2018/2980913
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832563301559566336
author Umut Gomceli
Srija Vangala
Cosmina Zeana
Paul J. Kelly
Manisha Singh
author_facet Umut Gomceli
Srija Vangala
Cosmina Zeana
Paul J. Kelly
Manisha Singh
author_sort Umut Gomceli
collection DOAJ
description Introduction. Systemic absorption of oral vancomycin is poor due to the size of the molecule and its pharmacokinetics. It has an elimination half life of 5–11 hours in patients with normal renal function. We present a rare case of ototoxicity after oral vancomycin administration and detectable serum vancomycin levels 24 hours after cessation of vancomycin. Case Presentation. A 42-year-old woman with a history of hypertension, diabetes mellitus, and previously treated Clostridium difficile colitis presented with abdominal pain and diarrhea for two weeks. Clostridium difficile infection was confirmed by PCR, and at the time of diagnosis and initiation of therapy, the patient had normal renal function. Vancomycin was initiated at a dose of 125 mg po q6h. After the third dose of oral vancomycin, the patient reported new symptoms of lightheadedness, sensations of “buzzing” and whistling of bilateral ears, and decreased perception of hearing described as “clogged ears.” The patient reported to the emergency department the next day due to worsening of these symptoms, and vancomycin dosing was reduced to every 8 hours; however, the patient reported the auditory symptoms persisted. On day three, vancomycin was discontinued with gradual resolution of symptoms over the next 12 hours. On day four, a serum random vancomycin level obtained 24 hours after the last dose was detectable at 2 mcg/dl. Temporal association of the patient’s symptoms and improvement with cessation of therapy along with a detectable vancomycin level indicates systemic absorption of oral vancomycin with subsequent ototoxicity. Discussion. The potential for absorption of oral vancomycin is not well described and is attributed to compromised intestinal epithelium allowing for increased drug absorption. Few studies suggested that oral vancomycin may result in therapeutic or even potentially toxic levels of serum vancomycin in patients with impaired renal function. Ototoxicity may be a transient or permanent side effect of vancomycin therapy and is related to high serum levels. Symptoms usually resolve after decreasing the dose or cessation of vancomycin. No detectable serum vancomycin levels were found in 98% of the patients treated with oral vancomycin in a prospective study. The described case is unusual because despite normal renal function, the patient still developed ototoxicity, and systemic absorption of the drug was confirmed with a measurable vancomycin level approximately 24 hours after the drug was stopped. Additionally, the only other medication prescribed to the patient at the time of vancomycin administration was metformin at a dose of 500 mg po bid which has no known idiosyncratic interactions potentiating adverse side effects to vancomycin. This case reflects that some patients may be more susceptible to increased systemic absorption via the oral route, and the possibility for ototoxicity should be considered and discussed with patients while prescribing oral vancomycin.
format Article
id doaj-art-8ad43798430a45f5a6e905b50872a1ee
institution Kabale University
issn 2090-6625
2090-6633
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series Case Reports in Infectious Diseases
spelling doaj-art-8ad43798430a45f5a6e905b50872a1ee2025-02-03T01:20:33ZengWileyCase Reports in Infectious Diseases2090-66252090-66332018-01-01201810.1155/2018/29809132980913An Unusual Case of Ototoxicity with Use of Oral VancomycinUmut Gomceli0Srija Vangala1Cosmina Zeana2Paul J. Kelly3Manisha Singh4Department of Internal Medicine, Bronx Lebanon Hospital Center, Bronx, NY, USADepartment of Internal Medicine, Bronx Lebanon Hospital Center, Bronx, NY, USADepartment of Internal Medicine, Bronx Lebanon Hospital Center, Bronx, NY, USADepartment of Internal Medicine, Bronx Lebanon Hospital Center, Bronx, NY, USADepartment of Internal Medicine, Bronx Lebanon Hospital Center, Bronx, NY, USAIntroduction. Systemic absorption of oral vancomycin is poor due to the size of the molecule and its pharmacokinetics. It has an elimination half life of 5–11 hours in patients with normal renal function. We present a rare case of ototoxicity after oral vancomycin administration and detectable serum vancomycin levels 24 hours after cessation of vancomycin. Case Presentation. A 42-year-old woman with a history of hypertension, diabetes mellitus, and previously treated Clostridium difficile colitis presented with abdominal pain and diarrhea for two weeks. Clostridium difficile infection was confirmed by PCR, and at the time of diagnosis and initiation of therapy, the patient had normal renal function. Vancomycin was initiated at a dose of 125 mg po q6h. After the third dose of oral vancomycin, the patient reported new symptoms of lightheadedness, sensations of “buzzing” and whistling of bilateral ears, and decreased perception of hearing described as “clogged ears.” The patient reported to the emergency department the next day due to worsening of these symptoms, and vancomycin dosing was reduced to every 8 hours; however, the patient reported the auditory symptoms persisted. On day three, vancomycin was discontinued with gradual resolution of symptoms over the next 12 hours. On day four, a serum random vancomycin level obtained 24 hours after the last dose was detectable at 2 mcg/dl. Temporal association of the patient’s symptoms and improvement with cessation of therapy along with a detectable vancomycin level indicates systemic absorption of oral vancomycin with subsequent ototoxicity. Discussion. The potential for absorption of oral vancomycin is not well described and is attributed to compromised intestinal epithelium allowing for increased drug absorption. Few studies suggested that oral vancomycin may result in therapeutic or even potentially toxic levels of serum vancomycin in patients with impaired renal function. Ototoxicity may be a transient or permanent side effect of vancomycin therapy and is related to high serum levels. Symptoms usually resolve after decreasing the dose or cessation of vancomycin. No detectable serum vancomycin levels were found in 98% of the patients treated with oral vancomycin in a prospective study. The described case is unusual because despite normal renal function, the patient still developed ototoxicity, and systemic absorption of the drug was confirmed with a measurable vancomycin level approximately 24 hours after the drug was stopped. Additionally, the only other medication prescribed to the patient at the time of vancomycin administration was metformin at a dose of 500 mg po bid which has no known idiosyncratic interactions potentiating adverse side effects to vancomycin. This case reflects that some patients may be more susceptible to increased systemic absorption via the oral route, and the possibility for ototoxicity should be considered and discussed with patients while prescribing oral vancomycin.http://dx.doi.org/10.1155/2018/2980913
spellingShingle Umut Gomceli
Srija Vangala
Cosmina Zeana
Paul J. Kelly
Manisha Singh
An Unusual Case of Ototoxicity with Use of Oral Vancomycin
Case Reports in Infectious Diseases
title An Unusual Case of Ototoxicity with Use of Oral Vancomycin
title_full An Unusual Case of Ototoxicity with Use of Oral Vancomycin
title_fullStr An Unusual Case of Ototoxicity with Use of Oral Vancomycin
title_full_unstemmed An Unusual Case of Ototoxicity with Use of Oral Vancomycin
title_short An Unusual Case of Ototoxicity with Use of Oral Vancomycin
title_sort unusual case of ototoxicity with use of oral vancomycin
url http://dx.doi.org/10.1155/2018/2980913
work_keys_str_mv AT umutgomceli anunusualcaseofototoxicitywithuseoforalvancomycin
AT srijavangala anunusualcaseofototoxicitywithuseoforalvancomycin
AT cosminazeana anunusualcaseofototoxicitywithuseoforalvancomycin
AT pauljkelly anunusualcaseofototoxicitywithuseoforalvancomycin
AT manishasingh anunusualcaseofototoxicitywithuseoforalvancomycin
AT umutgomceli unusualcaseofototoxicitywithuseoforalvancomycin
AT srijavangala unusualcaseofototoxicitywithuseoforalvancomycin
AT cosminazeana unusualcaseofototoxicitywithuseoforalvancomycin
AT pauljkelly unusualcaseofototoxicitywithuseoforalvancomycin
AT manishasingh unusualcaseofototoxicitywithuseoforalvancomycin